Extending the valproate registry to cover all antiepileptic drugs will be “prioritised in the next phase of its development” , the Department of Health and Social Care (DHSC) has said. The move follows recommendations in the Independent Medicines and Medical Devices Safety Review (/article/news/half-of-pharmacists-are-not-discussing-risks-of-valproate-with-patients) (IMMDSR), published in July 2020, in which the chair, Baroness Cumberlege, said that she wanted to see a registry for all women on antiepileptic drugs who become pregnant to include mandatory reporting and data relating to them and their children collated over lifetimes.
展开▼
